Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 88

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1
Chunk 88
---
 legislation
    in the United States, Europe and other foreign countries relating to the sale or pricing of pharmaceuticals;

    ●
    announcements
    by us of significant strategic partnerships, out-licensing, in-licensing, joint ventures, acquisitions or capital commitments;

    ●
    expiration
    or terminations of licenses, research contracts or other collaboration agreements;

    ●
    public
    concern as to the safety of therapeutics we, any licensees or others develop;

    ●
    success
    of research and development projects;

    ●
    developments
    concerning intellectual property rights or regulatory approvals;

    ●
    variations
    in us and our competitors’ results of operations;

    ●
    changes
    in earnings estimates or recommendations by securities analysts, if our common stock is covered by analysts;

    ●
    future
    issuances of common stock or other securities;

    ●
    general
    market conditions, including the volatility of market prices for shares of biotechnology companies generally, and other factors,
    including factors unrelated to our operating performance;

    ●
    political
    and economic instability, war or acts of terrorism (such as Russia’s invasion of Ukraine and the conflict in the Middle East)
    or natural disasters, emergence of a pandemic, or other widespread health emergencies (or concerns over the possibility of such an
    emergency, similar to the unprecedented COVID-19 pandemic); and

    ●
    the
    other factors described in this “Risk Factors” section.

These
factors and any corresponding price fluctuations may materially and adversely affect the market price of our common stock, which would
result in substantial losses by our investors.

Further,
the stock market in general, the Nasdaq Capital Market and the market for biotechnology companies in particular, have experienced extreme
price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of companies like theirs.
See also “General Risk Factors - “Unfavorable global economic conditions could adversely affect our business, financial
condition or results of operations.” Broad market and industry factors may negatively affect the market price of our common
stock regardless of our actual operating performance. In addition, a systemic decline in the financial markets and related factors beyond
our control may cause our share price to decline rapidly and unexpectedly. Price volatility of our common stock might be worse if the
trading volume of our common stock is low. In the past, following periods of market volatility, stockholders have often instituted securities
class action litigation